| Ytd | 176.30% | |
| 1y | 120.71% |
| Open | 3.79 | Prev Close | 3.80 | Low | 3.67 | High | 3.79 | Mkt Cap | 353.13M |
| Vol | 226.26K | Avg Vol | 1.21M | EPS | -1.96 | P/E | N/A | Forward P/E | -0.89 |
| Beta | 1.92 | Short Ratio | 3.17 | Inst. Own | 98.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-10 | 50-d Avg | 4.35 | 200-d Avg | 3.19 | 1yr Est | 9.50 |
ZNTL News
Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zental
Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zental
Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session
All of the securities to be sold in the proposed offering will be sold by the Company. The Company a
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zental
Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DE
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clini
Rodman & Renshaw initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy ratin
Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian
Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenoser
US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big ga
Mizuho analyst Graig Suvannavejh initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) wit
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clini
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinic
In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the comb
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinic
400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk
Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy
SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinic
Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June Results fro
SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clin
U.S. stocks mixed, Nasdaq up 100 points. Inflation rate surges to 3.3%. Japan's Nikkei 225 and C
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) shares are surging Friday after a Guggenheim analyst r
Dow Jones fell 100 points as Sun Pharma offered 12 billion to buy Organon, Organon shares jumped 26.
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clin
U.S. stocks traded higher, with the Dow Jones gaining around 25 points on Monday. Here are some big
U.S. stocks traded higher, with the Dow Jones gaining around 180 points on Thursday. Here are some b
On Friday, 497 companies set new 52-week lows.
Gainers
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tues